Central Indiana Corporate Partnership President and CEO David Johnson said there are still things he wants to accomplish before he retires in December to further strengthen the state’s key economic drivers, such as the life sciences and agrobiosciences sectors. Johnson announced last week that he would step down after ten years as head of the CICP. Prior to leading the business alliance, Johnson served as president and CEO of BioCrossroads, the state’s life sciences initiative.
In an Inside Indiana Business interview with Gerry Dick, Johnson reflected on the state’s life sciences sector just twenty years ago.
“There were all these life science companies that were here. I knew their leaders and they knew each other socially, but no one had ever thought about what we could do together,” Johnson said. “That’s how BioCrossroads started but dates back to 2001.”
The CICP is an alliance of leaders from Indiana’s business and research universities who work collectively to support the state’s economy and “foster long-term prosperity.” The organization grew from 30 to 113 people under Johnson’s leadership. It also added two of its six talent and industry initiatives – AgriNovus Indiana and Ascend Indiana.
“I have had the privilege of leading this organization for an important decade in the growth of our region and our state. I will miss the day-to-day engagement with leaders and colleagues, but I look forward to continuing to make some kind of productive contribution to the important work of promoting regional prosperity,” Johnson said in a press release, announcing his retirement. .
While Indiana was home to Eli Lilly and Co. (NYSE: LLY), Roche Diagnostics, Cook Medical and Zimmer Biomet (NYSE: ZBH), as well as major research institutions Indiana University and Purdue University, Johnson said the State was missing an opportunity for organizations to collectively position themselves in the industry.
“When it got organized, there was a lot more growth that was possible. There was more development. And you still see that happening today,” Johnson said. is to make Indiana a credible location for life science companies.”
With Johnson’s departure at the end of 2022, the CICP is revamping the leadership structure. The roles of President and CEO will be split into two.
CFO and COO Latoya Botteron will assume the role of chair, pending board approval in August. She will retain her role as CFO.
CICP has hired an executive consulting firm to lead the search for the next CEO.